Full text is available at the source.
Abstract
Among 49 programs that reached Phase II in type 2 diabetes, two-thirds of project arrests were unexplained or attributed to portfolio decisions.
- The clinical value of receptor-directed therapeutics is influenced by factors beyond target biology.
- A pharmaceutics-centered framework for type 2 diabetes incorporates multiple receptor targets, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
- Modality is a key factor in project arrests, indicating that the method of drug delivery may play a significant role.
- Deliverability is crucial for distinguishing between similar mechanisms, but it is inadequately addressed in existing public records.
Simplified